PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30244611-0	2018	An evaluation of memantine ER + donepezil for the treatment of Alzheimer"s disease.	Memantine	17-26	epiregulin	Homo sapiens	27-29	
30244611-6	2018	Namzaric , a fixed dose combination of donepezil and memantine extended-release (ER) (FDC memantine ER/donepezil), was recently approved by the U.S. Food and Drug Administration (FDA) for patients with moderate to severe AD and warrants further consideration as a clinically useful and advantageous pharmacotherapy in AD.	Memantine	53-62	epiregulin	Homo sapiens	81-83	
30244611-6	2018	Namzaric , a fixed dose combination of donepezil and memantine extended-release (ER) (FDC memantine ER/donepezil), was recently approved by the U.S. Food and Drug Administration (FDA) for patients with moderate to severe AD and warrants further consideration as a clinically useful and advantageous pharmacotherapy in AD.	Memantine	90-99	epiregulin	Homo sapiens	81-83	
30244611-7	2018	Areas covered: This review discusses the pharmacological properties, efficacy, and safety/tolerability data of this FDC memantine ER/donepezil as well as its benefits and disadvantages for patients and families.	Memantine	120-129	epiregulin	Homo sapiens	130-132	
30244611-9	2018	Expert opinion: Aside from its cost, FDC memantine ER/donepezil improves adherence to medication and reduces caregiver burden.	Memantine	41-50	epiregulin	Homo sapiens	51-53	
26519339-0	2015	Memantine ER/Donepezil: A Review in Alzheimer"s Disease.	Memantine	0-9	epiregulin	Homo sapiens	10-12	
26519339-1	2015	A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric ) is available in the USA for patients with moderate to severe Alzheimer"s disease (AD) on stable memantine and donepezil therapy.	Memantine	40-49	epiregulin	Homo sapiens	68-70	
26519339-3	2015	In a 24-week, phase III trial in patients with moderate to severe AD, addition of memantine ER 28 mg once daily to stable cholinesterase inhibitor (ChEI) therapy was more effective than add-on placebo on measures of cognition, global clinical status, dementia behaviour and semantic processing ability, although between-group differences on a measure of daily function did not significantly differ.	Memantine	82-91	epiregulin	Homo sapiens	92-94	
26519339-4	2015	In subgroup analyses in donepezil-treated patients, add-on memantine ER was more effective than add-on placebo on measures of cognition, dementia behaviour and semantic processing, although there were no significant between-group differences on measures of global clinical status and daily function.	Memantine	59-68	epiregulin	Homo sapiens	69-71	
26519339-5	2015	Memantine ER plus ChEI combination therapy was generally well tolerated in the phase III trial, with diarrhoea, dizziness and influenza occurring at least twice as often with add-on memantine ER as add-on placebo in donepezil-treated patients.	Memantine	0-9	epiregulin	Homo sapiens	10-12	
26519339-6	2015	Thus, memantine ER plus donepezil combination therapy is an effective and well tolerated treatment option for patients with moderate to severe AD.	Memantine	6-15	epiregulin	Homo sapiens	16-18	
20540654-0	2010	Memantine ER, a once-daily formulation for the treatment of Alzheimer"s disease.	Memantine	0-9	epiregulin	Homo sapiens	10-12	
25899711-3	2015	The memantine extended-release (ER) (Namenda XR( )) 28 mg once-daily capsule formulation was approved in the USA in 2010 and became available more recently.	Memantine	4-13	epiregulin	Homo sapiens	32-34	
25899711-3	2015	The memantine extended-release (ER) (Namenda XR( )) 28 mg once-daily capsule formulation was approved in the USA in 2010 and became available more recently.	Memantine	37-47	epiregulin	Homo sapiens	32-34	
25899711-4	2015	The potential advantages of memantine ER over the IR formulation include a more convenient dosage regimen and lower pill burden that may improve adherence to therapy; also, memantine ER capsules may be opened and the contents sprinkled on applesauce for patients who have difficulty swallowing.	Memantine	173-182	epiregulin	Homo sapiens	38-40	
25899711-4	2015	The potential advantages of memantine ER over the IR formulation include a more convenient dosage regimen and lower pill burden that may improve adherence to therapy; also, memantine ER capsules may be opened and the contents sprinkled on applesauce for patients who have difficulty swallowing.	Memantine	173-182	epiregulin	Homo sapiens	183-185	
25899711-5	2015	Memantine ER provides a higher total daily dosage than the recommended memantine IR regimen and pharmacokinetic data indicate greater exposure with the ER formulation, but the clinical implications of this are unclear, as the two formulations have not been assessed in a comparative clinical trial.	Memantine	0-9	epiregulin	Homo sapiens	10-12	
25899711-6	2015	The efficacy of memantine ER 28 mg once daily was demonstrated in a large, multinational, phase III trial, which showed that the addition of memantine ER to ongoing oral cholinesterase inhibitors improved key outcomes compared with cholinesterase inhibitor monotherapy, including measures of cognition and global status, which were the co-primary endpoints of the study.	Memantine	16-25	epiregulin	Homo sapiens	26-28	
25899711-6	2015	The efficacy of memantine ER 28 mg once daily was demonstrated in a large, multinational, phase III trial, which showed that the addition of memantine ER to ongoing oral cholinesterase inhibitors improved key outcomes compared with cholinesterase inhibitor monotherapy, including measures of cognition and global status, which were the co-primary endpoints of the study.	Memantine	16-25	epiregulin	Homo sapiens	151-153	
25899711-6	2015	The efficacy of memantine ER 28 mg once daily was demonstrated in a large, multinational, phase III trial, which showed that the addition of memantine ER to ongoing oral cholinesterase inhibitors improved key outcomes compared with cholinesterase inhibitor monotherapy, including measures of cognition and global status, which were the co-primary endpoints of the study.	Memantine	141-150	epiregulin	Homo sapiens	26-28	
20540654-5	2010	AREAS COVERED IN THIS REVIEW: The goal of this article is to review the once-daily memantine ER 28 mg formulation for the treatment of Alzheimer"s disease, which, by simplifying the dosage regimen, decreases the problems of medication adherence.	Memantine	83-92	epiregulin	Homo sapiens	9-11